Wednesday, August 10, 2016

In concert with the society’s mission to improve cancer patient outcomes through the development and application of cancer immunotherapy, SITC is proud to offer its first two-year translational fellowship opportunity, made possible through the generosity of Bristol-Myers Squibb.
• Fellowship Period: December 1, 2016 – November 30, 2018
• Amount: $200,000 ($100,000 per year for two years)
This award offers SITC young investigator members opportunities to obtain dedicated funding to catalyze their research and advance the field of cancer immunotherapy. This two-year award provides support to an individual who has an MD or combined MD/PhD degree and a vested interest in furthering the research and translation of cancer immunotherapy. This award recipient will also be recognized among peers and luminaries in the field at this year's SITC 31st Annual Meeting.
Click here to get more information, including the complete list of eligibility requirements. Applicants must be SITC members at time of submission to qualify. Not a SITC member? Get membership information and submit a membership application here.
Additional Award Opportunities
SITC will offer a total of 31 Young Investigator Awards to accepted abstract submitters, recognizing excellence in novel research and providing early career scientists with the experience necessary for successful careers. The abstract submission period is currently open and accepting applications through August 8, 2016. For information on these opportunities, including submission criteria and eligibility, click here.
About the Forward Fund
Since its inception, SITC has strongly supported the growth and achievements of young investigators in the field of cancer immunotherapy. Through the establishment of the Forward Fund, SITC has expanded funding opportunities to provide even more grants that will help attract the brightest young minds in cancer and/or immunology research to the cancer immunotherapy domain. Learn more here. |